Medtronic has reported a net income of $1.27bn for the second quarter (Q2) of fiscal year 2025 (FY 2025), marking a substantial rise from $911m in the same quarter of the previous year.

Net income attributable to the company was reported to be $1.27bn for the period which ended on 25 October 2024, compared to $909m in the prior year, indicating consistent growth.

Worldwide revenue for the quarter reached $8.403bn, an uptick of 5.3% as reported and 5% on an organic basis. 

Diluted earnings per share (EPS) also witnessed a significant leap, with a 46% increase to $0.99.

The cardiovascular portfolio was a strong performer, with revenue climbing to $3.10bn in Q2 FY 2025, up by 6.1% from $2.92bn reported in FY 2024.

In the neuroscience segment, Medtronic reported revenue of $2.45bn for the quarter, a 7.1% increase from $2.28bn in the previous year.  

The medical surgical portfolio saw a more modest rise of 1.2% from $2.10bn last year to $2.12bn this year.

The company’s diabetes portfolio demonstrated impressive growth with revenues surging by 12.4% to $686m in FY 2025 from $610m in Q2 of the previous year.

Non-GAAP net income and diluted EPS stood at $1.620bn and $1.26 respectively, representing a 3% decrease and a 1% increase, respectively.  

Medtronic chairman and CEO Geoff Martha said: "Our momentum is building as we keep executing on our commitments, delivering yet another consecutive quarter of strong results that came in ahead of expectations.

"As we look ahead, we're confident that this diversified growth will keep going, especially given the strength of our pipeline in high-impact markets that will allow us to benefit even more patients around the world."